{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denomUnitsSelected":"involved organs","denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"24"}],"units":"involved organs"}],"description":"Renal response - \\> 50% decrease in daily 24 hour proteinuria, without worsening renal insufficiency.\n\nHepatic response - decrease of 2 centimeters or more of the liver span and/or decrease of the alkaline phosphatase by 50% if elevated at baseline.\n\nCardiac response - decrease of 2 millimeters or more in mean left ventricular wall thickness in patients with baseline wall thickness \\> 11 mm or a decrease in New York Heart Association heart failure class.\n\nAutonomic nervous system response - resolution of orthostatic vital signs and symptoms, and resolution of symptoms of gastric atony or of functional ileus.\n\nGastrointestinal response - a greater than one grade improvement in diarrhea due to biopsy proven amyloid.\n\nPeripheral nervous system response - resolution of clinical signs of peripheral neuropathy.","groups":[{"description":"Melphalan Lenalidomide Dexamethasone\n\ndexamethasone: 40 mg once weekly\n\nlenalidomide: 10 mg/day Days 1-21\n\nmelphalan: 5 mg/m2 Days 1-4","id":"OG000","title":"Melphalan Revlimid and Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"one year","title":"Number of Organs Improved or Stable Based on Description Below:","type":"SECONDARY","typeUnitsAnalyzed":"involved organs","unitOfMeasure":"number of organs stable or improved"}